Cardiotoxicity and oncological treatments;Kardiotoxizität onkologischer therapien

Deutsches Arzteblatt International

Volumn 111, Issue 10, 2014, Pages 161-168

  Schlitt, Axel ^a,b   Jordan, Karin ^b   Vordermark, Dirk ^b   Schwamborn, Jürgen ^a   Langer, Thorsten ^c   Thomssen, Christoph ^b  

^a Paracelsus Harz Clinic Bad Suderode   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; LAPATINIB; LENALIDOMIDE; PACLITAXEL; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; ANGINA PECTORIS; BRADYCARDIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DYSPNEA; GERMANY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; REVIEW; THROMBOEMBOLISM; CHEMICALLY INDUCED; COMORBIDITY; EVIDENCE BASED MEDICINE; INCIDENCE; META ANALYSIS; MORTALITY; NEOPLASMS; RISK FACTOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; COMORBIDITY; EVIDENCE-BASED MEDICINE; HEART DISEASES; HUMANS; INCIDENCE; NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 84899532435     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0161     Document Type: Review

References (40)

1. Haberland J, Bertz J, Wolf U: Krebs in Deutschland 2005-2006. Häufigkeiten und Trends. Robert Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. 2010.
2. Kruger A, Wojnowski L: Cardiotoxicity of anthracyclines - an unsolved problem. Dtsch Arztebl 2006; 103(37): A-2393-7.
3. Hudson MM, Ness KK, Gurney JG, et al.: Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309: 2371-81.
4. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-52.
5. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-47.
6. Zhang S, Liu X, Bawa-Khalfe T, et al.: Identification of the molecular basis of doxorubicin-induced cardiotoxicitiy. Nat Med 2012; 18: 1639-42.
7. Ochsle K, Bokemeyer C: Adäquate Begleitmaßnahmen bei Tumortherapie mit Anthrazyklinen. Im Focus Onkologie 2007; 4: 55-9.
8. Oechsle K, Bokemeyer C: Kardiotoxizitäten bei Chemo- und Radiotherapie. Onkologe 2009; 15: 157-62.
9. El-Tokhy MA, Hussein NA, Bedewy AM, Barakat MR: XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients. Hematology. 2013 [Epub ahead of print].
10. Germanakis I, Anagnostatou N, Kalmanti M: Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008; 51: 327-33.
11. Hall C: Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257-60.
12. Sandri MT, Cardinale D, Zorzino L, et al.: Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248-52.
13. Paulides M, Wojnowski L: Chemotherapeutics-induced heart failure. Med Klin (Munich) 2007; 102: 574-8.
14. Lipshultz SE, Sallan SE: Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 1993; 11: 1199-203.
15. Tissières P, Beghetti M: Biomarker in der pädiatrischen Kardiologie. Paediatrica 2008; 19: 19-20.
16. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA: Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-9.
17. Bovelli D, Plataniotis G, Roila F: ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21: 277-82.
18. Jones S, Holmes FA, O'Shaughnessy J, et al.: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-83.
19. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
20. Coussens L, Yang-Feng TL, Liao YC, et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9.
21. Baselga J, Tripathy D, Mendelsohn J, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 1996; 14: 737-44.
22. Untch M, Muscholl M, Tjulandin S, et al.: First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-80.
23. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al.: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013; 21: 1021-8.
24. Romond EH, Jeong JH, Rastogi P, et al.: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792-9.
25. Slamon D, Eiermann W, Robert N, et al.: Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
26. Untch M, Rezai M, Loibl S, et al.: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-31.
27. Moja L, Tagliabue L, Balduzzi S, et al.: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.
28. Arbuck SG, Strauss H, Rowinsky E, et al.: A reassesment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; 15: 117-30.
29. Holmes FA, Madden T, Newman RA, et al.: Sequence-dependent alteration of doxorubicin pharmacokinetic by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 2713-21.
30. Maurer U, Härle M, Jungius KP, et al.: 5-Fluorouracil: cause of a fatal myocardial infarction during combined radiochemotherapy. Strahlenther Onkol 1996; 172: 257-60.
31. Patel B, Kloner RA, Ensly, et al.: 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilatators. Am J Med Sci 1987; 294: 238-43.
32. Burger AJ, Mannino S: 5-Fluorouracil induced coronary vasospasm. Am Heart J 1987; 114: 433-6.
33. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH: Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729-36.
34. Frickhofen N, Beck FJ, Jung B, et al.: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797-801.
35. Zhu X, Dahut WL, Parik CR: Risk of proteinuria and hypertension with bevacizumab, a monoclonal antibody against vascular endothelic growth factor: a systemic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93.
36. Hawkes EA, Okines AF, Plummer C, Cunningham D: Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011; 29: e560-2.
37. Berardi R, Caramanti M, Savini A, et al.: State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Crit Rev Oncol Hematol 2013; 88: 75-86.
38. Schmiedinger M, Zielinski CC, Vogl UM, et al.: Cardiac toxicity of sutininib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 2: 248-56.
39. Adams MJ, Lipsitz SR, Colan SD, et al.: Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-48.
40. Glanzman C, Kaufmann P, Jenni R, Hess OM, Huguenin P: Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51-62.